As we passed a terrible beginning of the week, we all learned that John Travolta may have been a hit in the 70′s but Greece is not the word.
Penny Stocks To Watch:
SMXI Volume trading has slowly picked up since we first profiled it and, similar to both OCNF and ANDS low volume trading in the past, could be in the early stage of a steady upward climb. The icloud legacy Steve Jobs dedicated to will be a benefit for an already well positioned SMXI.
Three stocks we love going into December:
Corinthian Colleges Inc. (COCO)
Corinthian Colleges, Inc. operates as a post-secondary education company in the United States and Canada. It offers various diploma programs; and associate’s, bachelor’s; and master’s degrees. COCO‘s diploma curricula includes medical assisting, medical insurance billing and coding, massage therapy, dental assisting, pharmacy technician, medical administrative assisting, automotive and diesel technology, HVAC, surgical technology, plumbing, electrical, licensed practical nursing, electronics, and computer technology.
Corinthians degree curriculum includes business administration, criminal justice, medical assisting, registered nursing, accounting, paralegal, marketing, computer information technology, legal assisting, hospitality management, applied service management, film, and video. COCO also provides master’s degree in business administration and criminal justice; and an online learning alternative to students pursuing education exclusively online.
As of June 30, 2011, Corinthian operated 122 colleges with 93,457 students in 26 states and the province of Ontario, Canada.
Corinthian Colleges, Inc. (NASDAQ: COCO) was upgraded by analysts at Piper Jaffray. The analysts now have a $5.00 price target on the stock.
COCO closed Wednesday at $2.40
LeapFrog Enterprises Inc. (LF)
LeapFrog Enterprises, Inc. designs, develops, and markets technology-based learning platforms and related proprietary content primarily for infants and children worldwide. LF offers interactive reading systems, such as the Tag reading system that focuses on fundamental reading skills and offers a library of software-based books; and Tag Junior reading system used for the introduction of younger children to books and reading.
LF also provides mobile learning system products, including Leapster platform, a handheld device with a multi-directional control pad and a touch-screen enabled by a built-in stylus; Leapster2 platform, a Web-connected version of Leapster; and Leapster Explorer to download digital content, such as games, e-Books, videos and flash cards. In addition, the company offers Scout collection, a line of learning toys that are Web-enabled and connect to the Learning Path; and My Own Leaptop, a Web-enabled customizable laptop; Fridge Collection, a line of magnetic learning toys that introduce letter names, letter sounds, spelling, and songs; Learn and Groove Collection, which include bilingual musical learning toys; and various products that address basic learning needs and milestones. Further, it provides LeapFrog Learning Path, an online tool enabling parents to track what their children are learning with Web-connected products; and LeapWorld, which allows children to play online games, customize their mobile learning and gaming experiences, access new content, watch trailers for new games, and view demonstrations. It sells its products directly to national and regional mass-market and specialty retailers; other retail stores and distributors; school-related distributors and resellers; and through online store and other Internet-based channels.
LeapFrog Enterprises Inc (NYSE: LF) was upgraded by analysts at Needham & Company from a “buy” rating to a “strong buy” rating. The analysts now have a $6.00 price target on the stock.
LF Closed up big Wednesday at $4.49
Aastrom Biosciences, Inc. (ASTM)
Aastrom Biosciences, Inc., a regenerative medicine company, engages in developing autologous cell therapies for the treatment of severe and chronic cardiovascular diseases. The companys autologous expanded cellular therapy technology uses single-pass perfusion to produce human cell products for clinical use. Its clinical development programs include CLI program, which is in phase IIb clinical development for the treatment of serious and advanced stage of peripheral arterial diseases; and DCM development program, which is in Phase II for the treatment of dilated cardiomyopathy (DCM). The company also has two ongoing U.S. Phase II trials investigating surgical and catheter-based delivery for its product in the treatment of DCM.
Aastrom Biosciences Inc (NASDAQ: ASTM) is now covered by analysts at Chardan Capital Markets. The analysts set a “buy” rating on the stock.
ASTM closed at $2.58 Wednesday.